Nova Eye Medical Ltd (ASX: EYE) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Nova Eye Medical Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$59.49 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
228.82 million
Earnings per share
-0.080
Dividend per share
N/A
Year To Date Return
9.12%
Earnings Yield
N/A
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Nova Eye Medical Ltd (ASX: EYE)
Latest News
⏸️ Investing
The Ellex Medical Lasers Limited share price is climbing higher
⏸️ Investing
Why these 4 ASX shares have jumped higher today
⏸️ Investing
Warren Buffett is Backing Trump's "Miracle Economy" And Loading Up On Stocks
⏸️ Investing
Why these 4 shares are getting SMASHED today
⏸️ Investing
Why the Ellex Medical Lasers Limited share price was SMASHED today
⏸️ Investing
Why Ellex Medical Lasers Limited shares have surged higher today
⏸️ Investing
Why small-cap Alcidion Group Ltd has gone gangbusters this month
⏸️ Investing
4 stocks soaring on the ASX today
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 21 Jul 2020 | $0.1350 | 100.00% | Special Cash | 29 Jul 2020 |
EYE ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Nova Eye Medical Ltd
Nova Eye Medical Ltd is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack minimallyinvasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The company's operating segment include AlphaRET and Glaucoma Surgical Devices, it generates maximum revenue from Glaucoma Surgical Devices. Geographically, it derives a majority of revenue from the United States of America.
EYE Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 14 May 2024 | $0.26 | $-0.01 | -3.77% | 123,928 | $0.27 | $0.27 | $0.26 |
| 13 May 2024 | $0.27 | $0.01 | 3.85% | 294,595 | $0.25 | $0.27 | $0.25 |
| 10 May 2024 | $0.26 | $0.02 | 8.16% | 235,648 | $0.25 | $0.26 | $0.25 |
| 09 May 2024 | $0.25 | $-0.02 | -7.69% | 599,819 | $0.26 | $0.26 | $0.25 |
| 08 May 2024 | $0.26 | $-0.01 | -3.77% | 68,108 | $0.26 | $0.27 | $0.26 |
| 07 May 2024 | $0.27 | $0.01 | 3.85% | 246,161 | $0.26 | $0.27 | $0.26 |
| 06 May 2024 | $0.26 | $-0.01 | -3.70% | 305,737 | $0.27 | $0.27 | $0.26 |
| 03 May 2024 | $0.27 | $-0.01 | -3.64% | 410,605 | $0.27 | $0.27 | $0.26 |
| 02 May 2024 | $0.28 | $0.01 | 3.77% | 280,937 | $0.27 | $0.28 | $0.27 |
| 01 May 2024 | $0.27 | $-0.02 | -7.14% | 540,773 | $0.28 | $0.29 | $0.27 |
| 30 Apr 2024 | $0.28 | $0.01 | 3.64% | 589,541 | $0.28 | $0.29 | $0.28 |
| 29 Apr 2024 | $0.28 | $0.00 | 0.00% | 814,489 | $0.27 | $0.28 | $0.27 |
| 26 Apr 2024 | $0.28 | $0.01 | 3.70% | 150,249 | $0.27 | $0.28 | $0.27 |
| 24 Apr 2024 | $0.27 | $0.01 | 3.77% | 536,808 | $0.27 | $0.28 | $0.27 |
| 23 Apr 2024 | $0.27 | $0.01 | 3.92% | 300,127 | $0.26 | $0.27 | $0.26 |
| 22 Apr 2024 | $0.26 | $0.01 | 4.00% | 132,153 | $0.26 | $0.26 | $0.26 |
| 19 Apr 2024 | $0.25 | $-0.02 | -7.55% | 129,987 | $0.27 | $0.27 | $0.25 |
| 18 Apr 2024 | $0.27 | $0.02 | 8.00% | 75,660 | $0.27 | $0.27 | $0.26 |
| 17 Apr 2024 | $0.25 | $0.00 | 0.00% | 152,467 | $0.25 | $0.25 | $0.25 |
| 16 Apr 2024 | $0.25 | $-0.02 | -7.55% | 316,058 | $0.26 | $0.27 | $0.25 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 15 Mar 2024 | Victor Previn | Issued | 1,233,948 | $259,129 |
Rights issue. As per announcement on 19-03-2024
|
| 15 Mar 2024 | Thomas (Tom) Spurling | Issued | 62,700 | $13,167 |
Rights issue.
|
| 15 Mar 2024 | Thomas (Tom) Spurling | Issued | 31,217 | $6,555 |
Rights issue.
|
| 15 Mar 2024 | Rahmon Coupe | Issued | 149,022 | $31,294 |
Rights issue.
|
| 15 Nov 2023 | Thomas (Tom) Spurling | Buy | 200,000 | $25,009 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Victor Previn | Executive DirectorExecutive Chairman | Jul 2001 |
Mr Previn is a professional engineer and one of the original founders of the Company. His career spans more than 35 years in both the ophthalmic laser industry and the wider ophthalmic device sector.Mr Previn held the position of Managing Director from 2003 to 2005. In July of 2005, Mr Previn was elected Chairman of the Board of Directors. He is also a member of Risk Committee.
|
| Mr Thomas (Tom) Anthony Spurling | Managing Director | Aug 2020 |
Mr Spurling served as the Chief Executive Officer of Ellex Medical Lasers from 2011 to 2019. Tom has close to 30 years of senior executive experience serving in a range of commercial and management roles in Australia and the United States.
|
| Mr Rahmon Coupe | Non-Executive Director | May 2013 |
Mr Coupe has more than 30 years' experience in the areas of corporate management, intellectual property management, contract negotiation, business development and engineering and has worked across a diverse range of industries, including information technology, life sciences and public broadcasting. Mr Coupe has held various project and engineering management roles for government research-based organisations, including the Defence Science and Technology Organisation (DSTO). He is currently a member Risk Committee.
|
| Mr Mike Southard | Non-Executive Director | Dec 2019 |
Mr Southard spent 26 years with Alcon Laboratories of Fort Worth, Texas, as Vice President of the Global Surgical business. Prior to this, he was an Executive with Beecham Laboratories (now SmithKline Beecham), and Cooper-Vision, which was acquired by Alcon Laboratories. Mike is currently involved in ophthalmology, dermatology and orthopaedics through his consulting company based in Portland, Oregon, USA. He has experience in both the International and US markets and maintains contacts with many of the world's key opinion leaders in all areas of eye surgery.
|
| Mr Daniel Webb | Non-Executive Director | Nov 2022 |
Mr Webb is based just outside Toronto, Canada and has a career that has spanned over 40 years in the marketing, sale and distribution of medical devices. After spending 10 years in various positions in ophthalmic device sales, Dan commenced his career with the medical laser company Coherent. In 1990 Dan established Coherent-AMT, now known as Clarion Medical Technologies (Clarion) to import, market, sell and distribute a range of medical devices, focusing on ophthalmic, aesthetic and surgical devices, in Canada. Clarion was sold to a multinational distribution business in 2020
|
| Mr Simon Ramsey Alexander Gray | Company Secretary | Jun 2020 |
-
|
| Liam Cook | Chief Financial Officer |
-
|
|
| Simon Ramsey Alexander Gray | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| National Nominees Limited | 35,438,325 | 18.62% |
| J P Morgan Nominees Australia Pty Limited | 15,386,778 | 8.08% |
| BOND STREET CUSTODIANS LIMITED | 9,359,138 | 4.92% |
| SEDICO PTY LTD <VICTOR PREVIN FAMILY A/C> | 7,266,980 | 3.82% |
| Ruminator Pty Ltd | 5,062,008 | 2.66% |
| Citicorp Nominees Pty Limited | 4,997,894 | 2.63% |
| PINE STREET PTY LTD | 4,200,000 | 2.21% |
| CANALA SUPER FUND PTY LTD | 3,504,095 | 1.84% |
| Viss Holdings Pty Ltd | 1,900,113 | 1.00% |
| INNOVATIVE GLAUCOMA SOLUTIONS LLC | 1,736,653 | 0.91% |
| Superhero Securities Limited | 1,600,108 | 0.84% |
| SING YING FAMILY PTY LTD | 1,459,358 | 0.77% |
| Hsbc Custody Nominees (Australia) Limited | 1,393,282 | 0.73% |
| SEDICO PTY LTD <VICTOR PREVIN SUPERFUND A/C> | 1,200,000 | 0.63% |
| Dinwoodie Investments Pty Ltd | 1,131,851 | 0.59% |
| MR TODD ALFRED CRANE | 1,092,279 | 0.57% |
| HSBC Custody Nominees (Australia) Limited (ii) | 1,058,331 | 0.56% |
| MR DOUGLAS ROBERT BUCHANAN & MRS ROBYN LORRAINE BUCHANAN | 1,050,000 | 0.55% |
| FAHEY SERVICES PTY LTD | 1,050,000 | 0.55% |
| MRS GLENIS NITA O'DONNELL | 1,030,000 | 0.54% |
